The research project of our group is translational with the aim to find new biomarkers of left ventricular remodeling post-infarction and heart failure. The team has expertise on coordinating recruitment of patients with cardiac disorders, clearly phenotyped for left ventricular remodeling post-infarction (REVE 1 (n=266) and REVE 2 (n=246) studies) or heart failure (PTHF (n=60) and INCA (n>2000) studies. These clinical studies allow recuperating plasma and serum samples that are used for differential proteomic and transcriptomic (miRNA and lncRNA) analyses. We have developed techniques allowing access and detection of plasma “deep” proteome. We have the expertise in discovery and validation of targets from proteomic (SELDI-TOF, 2D-DIGE, multiplex, ELISA) and miRNAomic (arrays, Q-RT-PCR).
Two approaches are currently developed: 1) a clinical approach with the purpose to develop clinical diagnostic applications for which we analyzed all the data obtained by system biology and; 2) a molecular approach with the purpose to understand the mechanisms underlying the targets (proteins, post-translational modified proteins, miRNA, lncRNA ) modulation in the pathologies studied. The discovery of new biological factors involved in the different cardiovascular pathologies would help to a better stratification of patients at risk.
